MedTrace Logo

Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus

NCT01188863 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2011-03-30

No results posted yet for this study

Summary

This protocol is intended to compare the effects of both a solid (tablet) and liquid oral dosage form of LX4211 in subjects with type 2 diabetes mellitus.

Conditions

Interventions

DRUG

300 mg LX4211 (150 mg tablets)

Single oral dose of two 150 mg tablets LX4211

DRUG

300 mg LX4211 (50 mg tablets)

Single oral dose of six 50 mg tablets LX4211

DRUG

300 mg LX4211 (liquid)

Single 30 mL dose of liquid oral solution LX4211 (10 mg/mL)

Sponsors & Collaborators

  • Lexicon Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Joel P. Freiman, MD, MPH · Lexicon Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2010-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01188863 on ClinicalTrials.gov